Instead, it has raised difficult questions about communication, preparedness, and the standards expected from public ...
MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200 million upfront. The deal gives MSD exclusive rights to the ...
BLANTYRE-(MaraviPost)-Joseph Mwanamveka has, in the past six months, demonstrated steady and results-oriented leadership in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results